Another shot for oral tolerance

Now, after analyzing data on the 1200 patients treated in Colloral trials through Phase II, as well as analyzing individual Phase II trials, AIMM (Lexington, Mass.) believes it has found the optimum dose and plans to move ahead with Phase III testing in RA.

According to President and CEO Robert Bishop, a dose-refinement Phase II study run in parallel to the 20 µg trials showed that 60 µg was actually the optimum dose. Complete data from the dose-refinement study, as well as data from a Phase II trial that tested the 20 µg dose of Colloral against hydroxychloroquine, have not yet been released...